This was the stock's second consecutive day of gains.

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

These eight projects took top marks in the three office subcategories for this year's Best Real Estate Deals awards program.

Incyte Corporation (NASDAQ:INCY), a biopharmaceutical company specializing in oncology and dermatology, finds itself at a critical juncture as it navigates the impending loss of patent protection ...

Shares of Incyte Co. (NASDAQ:INCY – Get Free Report) have been given a consensus recommendation of “Hold” by the nineteen ...

Incyte’s shares (currently trading at $60.02) have posted a disappointing 11.8% loss while the S&P 500 was down 1.7%. This ...

During a live event, Catherine J. Lee, MD, MS, discussed the mechanism of action of approved therapies for chronic ...

Content sponsored by Incyte Imagine living with a chronic condition, with symptoms that can be subtle and difficult to ...

Incyte and Morphosys’ Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope to provide a more convenient alternative to expensive and cumbersome ...

Incyte and MorphoSys' antibody therapy tafasitamab has been approved in Europe, promising to provide a more convenient alternative to expensive and cumbersome CAR-T therapies for patients with ...